AU2013331764B2 - N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer - Google Patents

N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer Download PDF

Info

Publication number
AU2013331764B2
AU2013331764B2 AU2013331764A AU2013331764A AU2013331764B2 AU 2013331764 B2 AU2013331764 B2 AU 2013331764B2 AU 2013331764 A AU2013331764 A AU 2013331764A AU 2013331764 A AU2013331764 A AU 2013331764A AU 2013331764 B2 AU2013331764 B2 AU 2013331764B2
Authority
AU
Australia
Prior art keywords
compound
cancer
compound according
formula
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013331764A
Other languages
English (en)
Other versions
AU2013331764A1 (en
Inventor
Maria Achab
Joanna Bakala
Michel BENECHIE
Jerome Bignon
Pascal Collin
Bernard Delpech
Maxim Egorov
Odile Thoison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2013331764A1 publication Critical patent/AU2013331764A1/en
Application granted granted Critical
Publication of AU2013331764B2 publication Critical patent/AU2013331764B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013331764A 2012-10-16 2013-10-14 N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer Ceased AU2013331764B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1259868 2012-10-16
FR1259868A FR2996847B1 (fr) 2012-10-16 2012-10-16 Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer
PCT/EP2013/071445 WO2014060366A1 (fr) 2012-10-16 2013-10-14 Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer

Publications (2)

Publication Number Publication Date
AU2013331764A1 AU2013331764A1 (en) 2015-05-21
AU2013331764B2 true AU2013331764B2 (en) 2017-11-16

Family

ID=47425104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013331764A Ceased AU2013331764B2 (en) 2012-10-16 2013-10-14 N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer

Country Status (8)

Country Link
US (1) US9546159B2 (https=)
EP (1) EP2909171B1 (https=)
JP (1) JP6423349B2 (https=)
AU (1) AU2013331764B2 (https=)
CA (1) CA2888379A1 (https=)
ES (1) ES2608781T3 (https=)
FR (1) FR2996847B1 (https=)
WO (1) WO2014060366A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3022244B1 (fr) * 2014-06-17 2016-07-01 Centre Nat De La Rech Scient (Cnrs) Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive
CN121154883A (zh) * 2020-05-25 2025-12-19 医工瑞思(福建)工程研究中心有限公司 一种大面积创伤急救敷料套件及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020411A1 (en) * 1998-10-08 2000-04-13 Pharma Mar, S.A. Cytotoxic alkaloids (halitulin)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019045A1 (en) * 1992-03-26 1993-09-30 E.I. Du Pont De Nemours And Company Arthropodicidal amides
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
WO2008064317A1 (en) * 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) * 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020411A1 (en) * 1998-10-08 2000-04-13 Pharma Mar, S.A. Cytotoxic alkaloids (halitulin)

Also Published As

Publication number Publication date
CA2888379A1 (fr) 2014-04-24
JP2015534958A (ja) 2015-12-07
ES2608781T3 (es) 2017-04-17
FR2996847B1 (fr) 2014-12-05
JP6423349B2 (ja) 2018-11-14
EP2909171A1 (fr) 2015-08-26
WO2014060366A1 (fr) 2014-04-24
FR2996847A1 (fr) 2014-04-18
AU2013331764A1 (en) 2015-05-21
US9546159B2 (en) 2017-01-17
EP2909171B1 (fr) 2016-09-28
US20150344460A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Liu et al. Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents
Liu et al. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors
Bayomi et al. Synthesis and biological evaluation of new curcumin analogues as antioxidant and antitumor agents: molecular modeling study
El Rayes et al. Convenient Synthesis and Anticancer Activity of Methyl 2-[3-(3-Phenyl-quinoxalin-2-ylsulfanyl) propanamido] alkanoates and N-Alkyl 3-((3-Phenyl-quinoxalin-2-yl) sulfanyl) propanamides
JP2022526266A (ja) がんを治療するための組成物及び方法
CA3017645C (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
Fan et al. Design, synthesis, and biological evaluation of a novel indoleamine 2, 3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
EP3180004A1 (en) Cancer therapeutics
KR20160012984A (ko) 벤조푸라논과 인돌 또는 아자인돌 콘쥬게이트 및 그의 제조방법과 용도
WO2018204370A1 (en) Cx3cr1 small molecule antagonists, and methods using same
AU2013331764B2 (en) N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
Nakagawa-Goto et al. Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity
WO2016077752A2 (en) Materials and method for inhibiting replication protein a and uses thereof
JP2016522223A (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
CA3033569A1 (en) Furanochalcones as inhibitors of cyp1a1, cyp1a2 and cyp1b1 for cancer chemoprevention
Xiao et al. Design, synthesis and biological evaluation of selective survivin inhibitors
JP2006521341A (ja) 生体還元により活性化されるスチルベンプロドラッグ
Yang et al. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors
US10512631B2 (en) Chalcone compounds
WO2014106763A1 (en) Pyridopyrazines as anticancer agents
Cheng et al. Synthesis of Curcumin-ferulic acid conjugate via Steglich esterification and anti-lung cancer activity of against Human non-small lung cancer cells (NSLCC)
Yao et al. Design, synthesis and biological assessment of erlotinib-1, 2, 3-triazole derivatives for anticancer applications
Generation et al. Molecular Sciences

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired